Anebulo Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$8,201,703 over the previous period. Total operating expenses were $8,308,755.
Profit Margin
| 2020 | 0 | -174.63K | |
|---|---|---|---|
| 2021 | 0 | -30.26M | |
| 2022 | 0 | -6.81M | |
| 2023 | 0 | -11.73M | |
| 2024 | 0 | -8.20M |
ANEB Income Statement (2020 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
Revenue | |||||
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 0 | 0 | 0 | 0 | 0 |
Gross profit | 0 | 0 | 0 | 0 | 0 |
Operating exp. | |||||
Research and development | 3.54M | 5.60M | 2.96M | 2.26M | 150K |
Selling and marketing | 4.8K | 0 | 0 | 0 | 23.21K |
Total operating expenses | 8.30M | 11.78M | 6.83M | 3.61M | 173.35K |
Operating income | -8.30M | -11.78M | -6.83M | -3.61M | -173.35K |
Other income (expenses), net | 107.05K | 51.26K | 5.55K | -26.63M | -1.28K |
Income before tax | -8.20M | -11.73M | -6.82M | -30.25M | -174.63K |
Income tax expense | 0 | -104.19K | -12.88K | 10.74K | -1.04K |
Net income | -8.20M | -11.73M | -6.81M | -30.26M | -174.63K |
Earnings per share | |||||
Basic EPS | -0.32 | -0.47 | -0.29 | -1.3 | -0.00 |
Diluted EPS | -0.32 | -0.47 | -0.29 | -1.3 | -0.00 |
| Data source | Data source | Data source |